Literature DB >> 30455614

Association between inflammatory bowel disease and uveal melanoma: case report of two young adults and a literature review.

Salvatore Cozzi1, Andrea Slocker Escarpa2, Daniel Lorenzo Parra3, Dina Najjari Jamal2, Josep Maria Caminal Mitjana3, Josep Maria Piulats R4, Ferran Guedea Edo2, Cristina Gutierrez Miguelez2.   

Abstract

INTRODUCTION: Uveal melanoma is a rare tumour caused by genetic factors and alterations in the immune response. Inflammatory bowel disease (IBD) is a multifactorial chronic inflammatory disorder characterized by an inappropriate or excessive immune response. The two main types of IBD are Crohn's disease (CD) and ulcerative colitis (UC). A diagnosis of IBD and the use of immunosuppressive drugs are both independently associated with an increased risk of developing skin melanoma. The association between IBD and uveal melanoma (UM) has not been previously described. CASES DESCRIPTION: Two young Caucasian men, aged 24 and 28, developed UM 3 and 15 years, respectively, after being diagnosed with IBD. Both received long-term treatment with immunomodulatory drugs, with periodic switching among the drugs due to the refractory nature of IBD. In both cases, melanoma was treated by brachytherapy with iodine-125 COMS plaque implant at a dose of 75 Gy. DISCUSSION: Chronic inflammation can promote cell proliferation and growth. The use of immunomodulatory drugs is associated with an increased risk of developing melanoma and non-melanoma skin cancer. The two patients described in this report both had long-standing IBD treated with immunomodulatory drugs. It seems reasonable to suggest that these two factors may have promoted the development of uveal melanoma. More studies are warranted to investigate and confirm this possible association.

Entities:  

Keywords:  Brachytherapy; Crohn's disease; IBD; Immunomodulatory drugs; Ulcerative colitis; Uveal melanoma

Year:  2018        PMID: 30455614      PMCID: PMC6234252          DOI: 10.1016/j.rpor.2018.10.002

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  21 in total

Review 1.  NF-κB, the first quarter-century: remarkable progress and outstanding questions.

Authors:  Matthew S Hayden; Sankar Ghosh
Journal:  Genes Dev       Date:  2012-02-01       Impact factor: 11.361

2.  Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System.

Authors:  Michael R McKenna; Derrick J Stobaugh; Parakkal Deepak
Journal:  J Gastrointestin Liver Dis       Date:  2014-09       Impact factor: 2.008

Review 3.  Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy.

Authors:  Angelo V Marzano; Alessandro Borghi; Pier Luigi Meroni; Carlo Crosti; Massimo Cugno
Journal:  Autoimmunity       Date:  2014-01-20       Impact factor: 2.815

Review 4.  Risk of cancer in inflammatory bowel disease: going up, going down, or still the same?

Authors:  Sushil K Garg; Edward V Loftus
Journal:  Curr Opin Gastroenterol       Date:  2016-07       Impact factor: 3.287

5.  Risk Factors and Clinical Outcomes in Patients with IBD with Melanoma.

Authors:  Loes H C Nissen; Marieke Pierik; Lauranne A A P Derikx; Elke de Jong; Wietske Kievit; Tim R A van den Heuvel; Alexander R van Rosendael; Elsemieke I Plasmeijer; Pieter Dewint; Rob H A Verhoeven; Lucy I H Overbeek; Iris D Nagtegaal; Frank Hoentjen; Andrea E van der Meulen-de Jong
Journal:  Inflamm Bowel Dis       Date:  2017-11       Impact factor: 5.325

6.  Clinical and histologic findings in patients with uveal melanomas after taking tumor necrosis factor-α inhibitors.

Authors:  Gena Damento; Shaheen C Kavoussi; Miguel A Materin; Diva R Salomão; Polly A Quiram; Saranya Balasubramaniam; Soranya Balasubramaniam; Jose S Pulido
Journal:  Mayo Clin Proc       Date:  2014-11-03       Impact factor: 7.616

Review 7.  Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?

Authors:  Yuehong Chen; Marcia Friedman; Gang Liu; Atul Deodhar; Cong-Qiu Chu
Journal:  Cytokine       Date:  2016-09-26       Impact factor: 3.861

Review 8.  Corrupt policemen: inflammatory cells promote tumor angiogenesis.

Authors:  Adrian Zumsteg; Gerhard Christofori
Journal:  Curr Opin Oncol       Date:  2009-01       Impact factor: 3.645

Review 9.  Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation.

Authors:  G Solinas; G Germano; A Mantovani; P Allavena
Journal:  J Leukoc Biol       Date:  2009-09-09       Impact factor: 4.962

Review 10.  Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis.

Authors:  Siddharth Singh; Sajan Jiv Singh Nagpal; Mohammad H Murad; Siddhant Yadav; Sunanda V Kane; Darrell S Pardi; Jayant A Talwalkar; Edward V Loftus
Journal:  Clin Gastroenterol Hepatol       Date:  2013-05-02       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.